Oruka Therapeutics (ORKA) Accumulated Expenses (2010 - 2026)
Oruka Therapeutics' quarterly Accumulated Expenses came in at $6.8 million in Q1 2026, up 731.91% year-on-year from $818000.0 in Q1 2025, and up 29.23% quarter-over-quarter from $5.3 million in Q4 2025.
Oruka Therapeutics has reported Accumulated Expenses for 17 years, with the latest figure at $6.8 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 731.91% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 731.91% YoY), and the FY2025 full-year result was $5.3 million, up 385.79% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $6.8 million, up from $5.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $6.8 million in Q1 2026, with the low at $84000.0 in Q1 2024.
- Average Accumulated Expenses over 5 years is $1.4 million, with a median of $324000.0 recorded in 2022.
- Year-over-year, Accumulated Expenses slumped 81.3% in 2022 and surged 3182.57% in 2025.
- Tracing ORKA's Accumulated Expenses over 5 years: stood at $173000.0 in 2022, then plunged by 42.2% to $100000.0 in 2023, then jumped by 984.0% to $1.1 million in 2024, then soared by 385.79% to $5.3 million in 2025, then gained by 29.23% to $6.8 million in 2026.
- The last three Accumulated Expenses figures came in at $6.8 million (Q1 2026), $5.3 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Mn |
| Dec 31, 2025 | 5.27 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 3.58 Mn |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 190,000.00 |
| Mar 31, 2023 | 235,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 333,000.00 |
| Jun 30, 2022 | 324,000.00 |
| Mar 31, 2022 | 168,000.00 |
| Dec 31, 2021 | 925,000.00 |
| Sep 30, 2021 | 146,000.00 |
| Jun 30, 2021 | 206,000.00 |
| Mar 31, 2021 | 255,000.00 |
| Dec 31, 2020 | 815,000.00 |
| Sep 30, 2020 | 221,000.00 |
| Jun 30, 2020 | 152,000.00 |
| Mar 31, 2020 | 189,000.00 |
| Dec 31, 2019 | 129,000.00 |
| Sep 30, 2019 | 158,000.00 |
| Jun 30, 2019 | 114,000.00 |
| Mar 31, 2019 | 206,000.00 |
| Dec 31, 2018 | 150,000.00 |
| Sep 30, 2018 | 184,000.00 |
| Jun 30, 2018 | 134,000.00 |
| Mar 31, 2018 | 239,000.00 |
| Dec 31, 2017 | 757,000.00 |
| Sep 30, 2017 | 193,000.00 |
| Jun 30, 2017 | 141,000.00 |
| Mar 31, 2017 | 241,000.00 |
| Dec 31, 2016 | 719,000.00 |
| Sep 30, 2016 | 162,000.00 |
| Jun 30, 2016 | 100,000.00 |
| Mar 31, 2016 | 152,000.00 |
| Dec 31, 2015 | 669,000.00 |
| Sep 30, 2015 | 114,000.00 |
| Jun 30, 2015 | 202,000.00 |
| Mar 31, 2015 | 123,000.00 |
| Dec 31, 2014 | 329,000.00 |
| Sep 30, 2014 | 99,000.00 |
| Jun 30, 2014 | 141,000.00 |
| Mar 31, 2014 | 111,000.00 |
| Dec 31, 2013 | 459,000.00 |
| Sep 30, 2013 | 75,000.00 |
| Jun 30, 2013 | 103,000.00 |
| Mar 31, 2013 | 60,000.00 |
| Dec 31, 2012 | 103,000.00 |
| Sep 30, 2012 | 80,000.00 |
| Jun 30, 2012 | 128,000.00 |
| Mar 31, 2012 | 78,000.00 |
| Dec 31, 2011 | 111,000.00 |
| Sep 30, 2011 | 75,000.00 |
| Jun 30, 2011 | 115,000.00 |
| Dec 31, 2010 | 175,000.00 |